Real World Data of Laboratory Changes and Immunophenotyping in Patients with Multiple Sclerosis Treated with Ofatumumab-Single Center Experience. [PDF]
BiomedicinesGudelj Zorić R +3 more
europepmc +1 more source
A retrospective pharmacovigilance study of ocrelizumab in multiple sclerosis: Analysis of the FDA Adverse Event Reporting System (FAERS) database. [PDF]
Medicine (Baltimore)Ma HY, Ma YB, Ye PJ, Bai R.
europepmc +1 more source
Infection and infestation-related adverse events of ocrelizumab: A disproportionality analysis using FDA adverse event reporting system. [PDF]
North Clin IstanbDuman NC.
europepmc +1 more source
Bach\u27s Oratorios: The Parallel German-English Texts, With Annotations [PDF]
, 2008 Bach, J. S., Marissen, Michael
core +1 more source
Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review. [PDF]
BMC MedBielekova B, Wu T, Kosa P, Calcagni M.
europepmc +1 more source
A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 Therapy. [PDF]
Neurol Clin PractGandelman S +3 more
europepmc +1 more source
ReViewing the World: A Review of the CBA Worldview project, International Television Coverage and the UK Media Industry [PDF]
, 2012 Jenner, Charlotte +2 more
core
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells. [PDF]
CellsGalota F +10 more
europepmc +1 more source
Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibodies for Multiple Sclerosis. [PDF]
J Clin MedBile F +8 more
europepmc +1 more source
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. [PDF]
J NeurolDelgado SR +3 more
europepmc +1 more source